ACAD — ACADIA Pharmaceuticals Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like gr… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$21.19
Market Cap$3.65B
Float127.3M
Shares Outstanding171.2M
P/E (Forward)61.73
P/E (TTM)9.65
Price/Sales (TTM)3.33
vs. Analyst Target+49.4% to analyst PT
Profit Margin34.30%
Operating Margin (TTM)-1.72%
Revenue (TTM)$1.10B
Earnings Growth (YoY)-81.80%
Dividend RateNone
Analyst Target Price$31.65 (20 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $442M -$282M $421M -$284M
2021 $484M -$168M $465M -$167M
2022 $517M -$216M $507M -$222M
2023 $726M -$61.3M $681M -$67.8M
2024 $958M $226M $876M $100M
2025 $1.07B $391M $983M $139M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $265M $26.7M
Sep 2025 $279M $71.8M
Dec 2025 $284M $274M
Mar 2026 $268M $3.6M

Ownership & Float

Insider Ownership0.3%
Institutional Ownership99.0%
Short Float8.8%
% of All Funds Holding3.84%
Number of Funds Holding316

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$21.69Near-term / short-term trend
Weekly40-Week SMA$23.45Medium-term trend
Weekly80-Week SMA$21.37Cyclical trend (business cycle)
Weekly200-Week SMA$20.61Secular trend (multi-year)
Monthly10-Month SMA$23.74Near-term monthly trend
Monthly20-Month SMA$21.15Medium-term monthly trend
Monthly40-Month SMA$21.28Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$14.70 support 1.50x 11 months ago

Historical Earnings Reactions (88 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.22% 0.00% 48.86% 17.27% -18.30%
1 Day -0.35% -1.30% 43.18% 20.99% -20.03%
1 Week -0.85% 0.55% 51.14% 34.46% -25.00%
2 Weeks 0.49% -1.52% 44.32% 96.28% -54.40%
1 Month 5.43% -0.98% 47.13% 130.90% -58.44%

Next earnings: July 25, 2026 (58 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan5.8%50.0%22
Feb2.4%63.6%22
Mar5.0%40.9%22
Apr0.1%45.5%22
May6.1%57.1%21
Jun-1.5%50.0%22
Jul5.3%59.1%22
Aug1.4%54.5%22
Sep2.4%50.0%22
Oct-2.5%45.5%22
Nov3.2%45.5%22
Dec6.0%54.5%22

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.46% 49.1% 1035
Tuesday -0.01% 45.5% 1137
Wednesday 0.02% 48.5% 1136
Thursday 0.19% 46.9% 1114
Friday 0.10% 47.2% 1110

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 99.0%

Insider Transactions — Smart Summary

Total insider ownership: 0.3%

12-Month Insider Activity Summary

Total Filings17
Net Value-$1.9M
Net Shares Change-9,626
% of Float-0.0%
C-Suite Filings14
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Daly James M -$670,983 1 1 sell
Brege Laura -$314,633.88 1 1 sell
Owen Adams Catherine Chief Executive Officer -$249,932.27 1 N/A
Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC -$245,021.68 2 N/A
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER -$235,531.413 2 N/A
Thompson Elizabeth H.Z. EVP, Head of Research and Dev -$73,749.45 1 N/A
Kihara James PRINCIPAL ACCOUNTING OFFICER -$41,895.349 1 N/A
GAROFALO ELIZABETH A. -$41,560.48 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-11-12 – 2025-11-19 3 3 -$1.0M 2 C-suite
2026-03-26 – 2026-04-07 7 5 -$690,249.221 7 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-26 Thompson Elizabeth H.Z. EVP, Head of Research and Dev -$73,749.45 Transaction at $21.47, now -1.3%
2026-03-26 Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER -$159,135.673 Transaction at $21.55, now -1.7%
2026-03-26 Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC -$82,530.68 Transaction at $21.47, now -1.3%
2026-03-26 Owen Adams Catherine Chief Executive Officer -$249,932.27 Transaction at $21.47, now -1.3%
2025-11-12 Daly James M -$670,983 Transaction at $22.37, now -5.3%
2025-06-05 Brege Laura -$314,633.88 Transaction at $21.78, now -2.7%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for ACADIA Pharmaceuticals Inc (ACAD) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ACAD on Trend Edge →